文献速递前列腺癌

澳大利亚人群队列中中高危前列腺癌根治性放疗联用雄激素剥夺治疗的机构差异

Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
PubMed 文献 · BJU Int · 2017-08-19

基于澳大利亚维多利亚州前列腺癌结局登记的前瞻性人群队列,纳入2010年1月至2015年12月接受根治性前列腺放疗的1806例中高危前列腺癌患者,评估雄激素剥夺治疗(ADT)使用模式。64%患者接受ADT联合放疗,高危患者ADT使用率(84%)高于有利中危(32%)和不利中危(46%)患者(P<0.001)。公立机构(66% vs 私立47%)和区域中心(78% vs 都市59%)ADT使用率更高(P<0.001),且ADT使用从2010年50%增至2015年64%(P<0.001)。

要点

  • 1806例中高危前列腺癌放疗患者中,1155例(64%)接受ADT联合放疗。
  • 高危患者ADT使用率84%,高于有利中危32%和不利中危46%(P<0.001)。
  • 公立机构ADT使用率66% vs 私立47%,区域中心78% vs 都市59%(P<0.001)。

核心结论

  • 这是澳大利亚亚地区最大的当代系列报告根治性前列腺放疗联用ADT的模式。
  • ADT使用随时间呈增加趋势,但在某些可能获益的患者群体中ADT仍似乎未被充分利用:约五分之一高危和一半不利中危前列腺癌患者未接受ADT联合放疗。
  • 公立与私立、都市与区域机构之间ADT使用存在显著差异。

研究设计与样本

  • 前瞻性人群队列研究,数据来自澳大利亚维多利亚州前列腺癌结局登记。
  • 纳入2010年1月至2015年12月接受根治性前列腺放疗的中危和高危前列腺癌患者1806例。
  • 主要结局为ADT使用情况;采用卡方趋势检验评估ADT使用的时间趋势,多因素逻辑回归评估患者、肿瘤、治疗相关因素及治疗机构对ADT使用可能性的影响。

主要发现

  • 1806例中,199例(11%)为有利NCCN中危(仅一个中危特征、主要Gleason分级3、<50%活检针受累),687例(38%)为不利NCCN中危,920例(51%)为高危。
  • 1155例(64%)接受ADT联合放疗;高危患者ADT使用率84%,高于有利中危32%和不利中危46%(P<0.001)。
  • 公立机构ADT使用率66% vs 私立机构47%(P<0.001);区域中心78% vs 都市机构59%(P<0.001)。
  • ADT使用率从2010年50%增至2015年64%(P<0.001)。
  • 多因素分析(校正年龄、肿瘤相关因素、治疗年份和近距离放疗推量)显示,治疗机构(公立和区域)仍独立与ADT使用可能性增加相关:中危患者中区域和公立机构ADT使用可能性分别为2.7倍(95%CI 1.9-3.9;P<0.001)和2.8倍(95%CI 1.4-5.3;P=0.002);高危患者中区域和公立机构分别为3.1倍(95%CI 1.7-5.7;P<0.001)和3.0倍(95%CI 1.7-5.4;P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the pattern of use of androgen deprivation therapy (ADT) with definitive radiotherapy (RT) in men with prostate cancer (PCa) in a population-based study in Australia. PATIENTS AND METHODS: This is a prospective cohort of men with intermediate- and high-risk PCa, captured in the population-based Prostate Cancer Outcome Registry Victoria, who were treated with definitive prostate RT between January 2010 and December 2015. The primary outcome of interest was ADT utilization. Chi-squared test for trend was used to evaluate the temporal trend in the use of ADT over the study period. Multivariate logistic regressions were used to evaluate the effects of patient-, tumour- and treatment-related factors, and treatment institutions (public/ private and metropolitan/ regional) on the likelihood of ADT utilization. RESULTS: A total of 1806 men were included in the study, 199 of whom (11%) had favourable National Comprehensive Cancer Network (NCCN) intermediate-risk disease (i.e. only one intermediate-risk feature, primary Gleason grade 3, and <50% biopsy core involved), 687 (38%) had unfavourable NCCN intermediate-risk disease, and 920 (51%) had high-risk disease. Of the 1806 men, 1155 (64%) received ADT with RT. Men with NCCN high-risk PCa (84%) were more likely to have ADT than men with favourable NCCN intermediate-risk (32%) and unfavourable NCCN intermediate-risk (46%) PCa (P < 0.001). Men treated in public institutions (66%, vs 47% in private institutions; P < 0.001) and regional centres (78%, vs 59% in metropolitan institutions; P < 0.001) were more likely to receive ADT. There was a trend towards an increase in ADT utilization from 50% in 2010 to 64% in 2015 (P < 0.001). In multivariate analyses (adjusting for age, tumour-related factors, year of treatment and use of brachytherapy boost), treatment institution (public and regional) remained independently associated with increased likelihood of ADT utilization. Men with intermediate-risk PCa treated in regional and public institutions were 2.7 times (95% confidence interval [CI] 1.9-3.9; P < 0.001) and 2.8 times (95% CI 1.4-5.3; P = 0.002), more likely to receive ADT with RT, respectively, while men with high-risk PCa treated in regional and public institutions were 3.1 times (95% CI 1.7-5.7; P < 0.001) and 3.0 times (95% CI 1.7-5.4; P < 0.001), more likely to receive ADT with RT, respectively. CONCLUSION: This is the largest Australasian contemporary series reporting on the pattern of use of ADT with definitive prostate RT. While there was an increasing trend towards use of ADT over time, ADT still appeared to be underutilized in certain groups of patients who may benefit from ADT, with approximately one in five men with high-risk and one in two with unfavourable intermediate-risk PCa not receiving ADT with RT. There was notable variation in the use of ADT between public vs private and metropolitan vs regional institutions.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Ong WL, Foroudi F, Evans S, et al. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer. BJU Int. 2017. PMID: 28749017. doi:10.1111/bju.13969

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。